share_log

American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting

American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting

美國腫瘤網絡宣佈在2024年ASCO年會上展示的研究研究。
GlobeNewswire ·  06/04 20:00

AON physicians and leaders present their latest cancer findings with fellow thought leaders at the annual conference.

AON的醫生和領導者們與其他思想領袖一起在年會上展示他們最新的癌症研究發現。

American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting

美國腫瘤網絡宣佈在ASCO 2024年年會上展示的研究研究

From left to right: Ruemu E. Birhiray, MD, medical oncologist at Hematology Oncology of Indiana; Ralph V. Boccia, MD, FACP, medical oncologist at Center for Cancer & Blood Disorders; Arvind Chaudhry, MD, PhD, medical oncologist at Summit Cancer Centers; Christopher Chay, MD, medical oncologist at Messino Cancer Centers; Stephen "Fred" Divers, MD, medical oncologist at Genesis Cancer and Blood Institute; and Brian Mulherin, MD, medical oncologist at Hematology Oncology of Indiana.
從左到右：Ruemu E. Birhiray，在印第安納血液腫瘤內科的醫學腫瘤學家；Ralph V. Boccia，在癌症和血液疾病中心的醫學腫瘤學家；Arvind Chaudhry，在峯會癌症中心的醫學腫瘤學家；Christopher Chay，在梅西諾癌症中心的醫學腫瘤學家；Stephen "Fred" Divers，在創世紀癌症和血液研究所的醫學腫瘤學家以及Brian Mulherin，在印第安納血液腫瘤內科的醫學腫瘤學家。

FORT MYERS, Fla., June 04, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation's fastest-growing networks of community oncology practices, is pleased to announce that several research studies, co-authored by AON physicians and leaders, were accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. The meeting was held from May 31 to June 4 in Chicago.

2024年6月4日，《環球新聞》報道：全美最快增長的社區腫瘤醫療實踐網絡之一，美國腫瘤網絡（納斯達克：AONC）很高興宣佈，幾篇與AON的醫生和領導者合作的研究，已被接受參加2024年美國臨床腫瘤學會（ASCO）年會。該會議於5月31日至6月4日在芝加哥舉行。

The following abstracts were selected for either poster discussions, presentations or online publication after rigorous review.

在經過嚴格審核後，以下摘要被選爲海報討論、演示或在線發佈。

  • Ruemu Ejedafeta Birhiray, MD, of Hematology Oncology of Indiana, co-authored the following studies:
    • "Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1)."
    • "Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2)."
  • Ralph V. Boccia, MD, FACP, of The Center for Cancer and Blood Disorders, co-authored the following studies:
    • "Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab."
    • "Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy."
    • "Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6."
  • Arvind Chaudhry, MD, PhD, of Summit Cancer Centers, co-authored the following studies:
    • "BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)."
    • "BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma."
    • "Phase 1 trial of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in monotherapy and combination with pembrolizumab in patients with advanced solid tumors."
    • "YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial."
    • "A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors."
  • Christopher Chay, MD, of Messino Cancer Centers, co-authored the following study:
    • "Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy."
  • Stephen "Fred" Divers, MD, of Genesis Cancer and Blood Institute and AON's chief medical officer, and Brian Mulherin, MD, of Hematology Oncology of Indiana, co-authored the following study:
    • "Assessing quality of care in early stage resected stage non-small cell lung cancer (NSCLC): An evaluation of epidermal growth factor receptor (EGFR) testing and adjuvant (adj) therapy (tx)."
  • Tamara Weinberg, RN, BSN, OCN, ONN-CG, AON's pharmacy RN supervisor, authored the following study, which will be published only on the ASCO website:
    • "Can a medically integrated oncology pharmacy decrease waste and avoidance?"
  • Ruemu Ejedafeta Birhiray，印第安納血液腫瘤內科醫生共同撰寫了以下研究：
    • "第3期試驗評估Odronextamab與調查員的選擇相比在以前未治療的濾泡性淋巴瘤（OLYMPIA-1）中的療效和安全性。"
    • "第3期試驗評估Odronextamab與化療的療效和安全性相比，與以前未治療的濾泡性淋巴瘤的利妥昔單抗合併化療（OLYMPIA-2）相比。"
  • Ralph V. Boccia，癌症和血病中心的醫學腫瘤學家，共同撰寫了以下研究：
    • "基線ENPP1和cGAS在腫瘤內免疫激活和治療後的臨床結果方面與一類口服ENPP1抑制劑RBS2418，單獨或與pembrolizumab聯合治療的相關性。"
    • "用半相同重組細胞免疫療法BRIA-IMT治療晚期/轉移性乳腺癌（aMBC）的結果。"
    • "第2期EPCORE NHL-6中皮下Epcoritamab（SC epcor）用於複發性或難治性的瀰漫大B細胞淋巴瘤（DLBCL）和濾泡性淋巴瘤（FL）的結果。"
  • Summit Cancer Centers的Arvind Chaudhry，MD，PhD，共同撰寫了以下研究：
    • "BELLWAVE-010：一個關於奈替布替尼加文尼托克塞和利妥昔單抗（VR）治療以前治療過的患者（pts）復發/難治性慢性淋巴細胞白血病（CLL）/小細胞淋巴瘤（SLL）的第3期研究。"
    • "BELLWAVE-011：一個關於奈替布替尼與未處理過的慢性淋巴細胞白血病/小細胞淋巴瘤的第3期隨機試驗。"
    • "TU2218的第1期試驗，TGFβ-RI和VEGF-R2的雙重抑制劑，單獨或與Pembrolizumab合用於晚期實體瘤患者。"
    • "YL202 / BNT326，針對HER3的ADC，在局部晚期或轉移性非小細胞肺癌和乳腺癌患者中：首項第I期試驗的初步結果。"
    • "一項I / II期，開放標籤，多中心研究，旨在評估HB0036的安全性、藥代動力學、藥效學和療效，用於晚期實體瘤患者。"
  • Messino Cancer Centers的Christopher Chay，MD，共同撰寫了以下研究：
    • "聯盟A222001：關於氧布他定和安慰劑治療從事雄性抑制治療的熱潮患者的隨機、雙盲、安慰劑對照第II期研究。"
  • Genesis Cancer and Blood Institute和AON的首席醫學官Stephen "Fred" Divers，MD，以及Hematology Oncology of Indiana的Brian Mulherin，MD，共同撰寫了以下研究：
    • 評估早期切除期非小細胞肺癌(NSCLC)的護理質量：表皮生長因子受體(EGFR)檢測和輔助(adh)治療(txs)的評估。
  • AON的藥房護士主管Tamara Weinberg，RN，BSN，OCN，ONN-CG，撰寫了以下研究，將只在ASCO網站上發佈：
    • 醫學整合腫瘤學藥房能減少浪費和逃避嗎？

"It is always an honor to share our research and latest findings with our fellow colleagues at events such as this one," said Dr. Boccia who also serves as chairperson of the AON Research Committee. "The ASCO platform allows us to connect with like-minded oncologists and other healthcare leaders and accelerate the impact of our work. By contributing to the collective knowledge of clinical oncology, we are dedicated to the advancement of the field and improving patient care and outcomes."

博茨博士說："在這樣的活動上與同行分享我們的研究和最新發現總是很榮幸。ASCO平台使我們能夠與志同道合的腫瘤學家和其他醫療領導人聯繫，加速我們的工作影響。通過爲臨床腫瘤學的集體知識做出貢獻，我們致力於推動該領域的發展並改善患者護理和結局。"

"Investing in oncology research is not just about developing new drugs or treatment approaches," said Dr. Divers. "It is about pushing the boundaries of our understanding of cancer and identifying its vulnerabilities. Every piece of knowledge gained through dedicated research efforts brings us closer to developing personalized treatment plans, improving early detection, and ultimately, finding a cure for the devastating disease. We are proud to be contributing to this critical endeavor, and the ASCO annual meeting plays a vital role in accelerating the pace of scientific progress."

迪弗斯博士說： "投資腫瘤學研究不僅僅是開發新藥物或治療方法，也是推動我們對癌症的理解界限，發現其弱點。通過致力於研究工作獲得的每一份知識，使我們更接近於制定個性化的治療計劃，改善早期治療，最終找到治癒這種毀滅性疾病的方法。我們爲能夠對這一關鍵事業做出貢獻而感到自豪，ASCO年會在加速科學進步的步伐中發揮着至關重要的作用。"

"We are thrilled to have several of our esteemed physicians/leaders present their groundbreaking studies at the ASCO Annual Meeting," said Todd Schonherz, AON's chief executive officer. "This event gathers the brightest minds in clinical oncology and having our physicians and leaders represented is a tremendous honor. At AON, we are dedicated to fostering a culture of continuous learning and innovation. We empower our physicians/leaders to push the boundaries of the field, and their participation is a testament to their dedication to improving oncology and achievements in the industry. These presentations not only showcase their expertise but also contribute valuable insights to the advancement of cancer care for years to come."

"我們非常高興能夠在ASCO年會上看到我們幾位傑出的醫生/領導人介紹他們的開創性研究結果。" AON的首席執行官託德·肖納赫茲(Todd Schonherz)說："這個活動聚集了臨床腫瘤學中最聰明的頭腦，我們的醫生和領導人的代表是一項巨大的榮譽。在AON，我們致力於營造一個不斷學習和創新的文化。我們授權醫生/領導人推動該領域的界限，他們的參與是對任務改善腫瘤學和行業成就的投入。這些演示不僅展示了他們的專業知識，也爲未來的癌症護理提供了有價值的見解。"

ASCO is a leading professional organization for oncology physicians and professionals. The annual meeting brings together oncology physicians and thought leaders for networking opportunities and more than 145 hours of educational and informational sessions.

ASCO是腫瘤學醫師和專業人員的領先專業組織。年會聚集了腫瘤學醫師和思想領袖，提供145多小時的教育和信息，以及網絡機會。

AON has many practices that are actively engaged in groundbreaking clinical research initiatives, with four sites designated as strategic research sites for Sarah Cannon Research Institute. As part of our commitment to advancing medical knowledge and patient care, AON practices provide opportunities for participation in over 150 clinical trials. These services are conveniently accessible at a community level, ensuring patients receive cutting-edge treatments close to home, enhancing their overall cancer journey.

AON有許多研究機構積極參與開創性臨床研究，其中四個機構被指定爲Sarah Cannon Research Institute的戰略研究站點。作爲推進醫學知識和病人關愛的承諾一部分，AON機構爲超過150項臨床試驗提供參與機會。這些服務在社區層面上方便地獲得，確保患者可以在家附近接受先進治療，提高他們的整體癌症治療體驗。

For more information about AON, visit .

欲了解更多信息，請訪問。

###

###

About American Oncology Network

關於美國腫瘤學網絡

American Oncology Network (AON) (Nasdaq: AONC) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON's rapidly expanding network represents more than 240 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. Learn more at .

美國腫瘤學網絡(AON) (納斯達克: AONC)是一家由醫生和經驗豐富的醫療保健領導人組成的聯盟，旨在確保社區腫瘤學和其他專業的長期成功和可持續性。成立於2018年的AON快速擴大的網絡代表了21個州的240多名提供者。AON通過以醫生爲主導的模式開拓創新的醫療保健解決方案，促進以價值爲基礎的護理，提高患者的治療效果，同時降低成本，擴大碩果累累的品質護理的接入渠道。AON爲網絡醫生提供所需的工具，使他們能夠獨立發展，同時提供綜合支持，集成的增收的附屬服務和實踐管理專業知識，使醫生能夠集中精力爲每一位患者提供最高水平的護理。AON致力於通過解決癌症護理中的不平等現象，例如提高關愛的效果來促進健康平等。AON專注於創新和協作，正在塑造未來的社區腫瘤學。欲了解更多信息，請訪問。

Attachment

附件

  • American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting
  • 美國腫瘤學網絡宣佈在2024年ASCO年會上發表的研究成果
CONTACT: Caroline Hewitt American Oncology Network 941.224.8736 Caroline.Hewitt@AONcology.com 
聯繫人：卡羅琳·休伊特美國腫瘤學網絡941.224.8736薩羅琳e.Hewitt@AONcology.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論